LadRx (LADX) 10-K2012 FY Annual report

Filed: 11 Mar 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: aldoxorubicin, Annex, behavior, cardiac, compassionate, condensed, dacomitinib, ductal, earliest, fluoropyrimidine, fourth, gemcitabine, ibrutinib, Iclusig, Infinity, Instruction, likelihood, lymph, nadir, neutropenia, NOL, opposed, par, postulated, proven, simply, speculative, spleen, Synribo, TKI, Votrient

Removed: accumulating, accumulation, age, Amnolake, applied, Ariad, arose, ASU, auditing, Avenue, Beckman, BioMarin, brand, breathing, Bulletin, complication, consecutive, consolidate, dasatinib, defining, die, Diego, differentiate, discontinued, dollar, dyspnea, ending, enrolled, escalating, exempt, existed, expression, fatal, fatigue, fever, forecasting, funded, Geyer, guarantee, Hagop, hematologic, increasing, incremental, incurring, Israel, Kantarjian, leukemic, library, Louisiana, Madison, Merck, mg, microbiology, misleading, morphologic, naturally, nilotinib, older, Onyx, optimal, pazopanib, pericardial, poor, prolongation, properly, prospectively, pulmonary, QTc, RAS, recommend, recurrence, regain, rent, represented, resumed, rhythm, scheduled, security, selectively, SmithKline, Southwestern, sublease, swelling, syndrome, TRF, unacceptable, undergo, veterinary, Virtually, Xencor

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

LADX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

CytRx Corporation

Los Angeles, California

We hereby consent to the incorporation by reference in the Registration Statements on Form S3 (Nos. 333-100947, 333-109708, 333-106629, 333-109708, 333-133269, 333-142591, 333-147605, 333-170437 and 333-185308) and Form S8 (Nos. 333-84657, 333-68200, 333-91068, 333-93305, 333-123339 and 333-163212) of CytRx Corporation of our reports dated March 11, 2013, relating to the consolidated financial statements and schedule, and the effectiveness of CytRx Corporation’s internal control over financial reporting, which appear in this Form 10-K.

/s/ BDO USA, LLP

Los Angeles, California

March 11, 2013